MoonLake Immunotherapeutics (MLTX) Misses Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Join SI Premium – FREE
MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q1 EPS of ($0.98), $0.09 worse than the analyst estimate of ($0.89).
For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Bernstein SocGen Group Upgrades Wayfair (W) to Outperform
- Macquarie Upgrades DiDi Global (DIDIY) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
